Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| RVMDRevolution Medicines Inc | $555.3M | 14.2% | +3.8% |
| KYMRKymera Therapeutics Inc | $444.0M | 11.4% | −29.6% |
| Xoma Royalty CorporationCUSIP 98419J206 | $322.7M | 8.3% | +193.1% |
| MLTXMoonlake Immunotherapeutics | $311.5M | 8.0% | |
| Gh Research PLCCUSIP G3855L106 | $232.5M | 5.9% | |
| GPCRStructure Therapeutics Inc | $180.7M | 4.6% | −2.7% |
| NKTRNektar Therapeutics | $166.9M | 4.3% | −6.6% |
| MIRMMirum Pharmaceuticals Inc | $123.6M | 3.2% | −33.4% |
| XNCRXencor Inc | $114.9M | 2.9% | |
| Alkermes PLCCUSIP G01767105 | $112.9M | 2.9% | +7.7% |
| GLUEMonte Rosa Therapeutics Inc | $108.0M | 2.8% | |
| CGEMCullinan Therapeutics Inc | $104.7M | 2.7% | |
| PVLAPalvella Therapeutics Inc Ne | $102.8M | 2.6% | −30.0% |
| ZYMEZymeworks Inc | $95.4M | 2.4% | −2.3% |
| KURAKura Oncology Inc | $92.7M | 2.4% | |
| IRONDisc Medicine Inc | $84.4M | 2.2% | −9.3% |
| STOKStoke Therapeutics Inc | $83.4M | 2.1% | |
| OLMAOlema Pharmaceuticals Inc | $66.3M | 1.7% | |
| ANNXAnnexon Inc | $49.7M | 1.3% | |
| Crescent Biopharma Inc.CUSIP G2545C104 | $49.5M | 1.3% | |
| Ac Immune SaCUSIP H00263105 | $47.2M | 1.2% | |
| TYRATyra Biosciences Inc | $47.1M | 1.2% | −25.3% |
| STROSutro Biopharma Inc | $41.6M | 1.1% | |
| IMCRImmunocore Hldgs PLC | $41.1M | 1.1% | |
| AVTXAvalo Therapeutics Inc | $38.4M | 1.0% | +27.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| PVLAPalvella Therapeutics Inc Ne | December 31, 2024 | +1173.5% | $102.8M |
| RVMDRevolution Medicines Inc | June 30, 2020 | +493.2% | $555.3M |
| MIRMMirum Pharmaceuticals Inc | September 30, 2023 | +270.5% | $123.6M |
| KYMRKymera Therapeutics Inc | September 30, 2020 | +254.9% | $444.0M |
| GLUEMonte Rosa Therapeutics Inc | December 31, 2024 | +248.7% | $108.0M |
| ZYMEZymeworks Inc | December 31, 2022 | +232.6% | $95.4M |
| GPCRStructure Therapeutics Inc | March 31, 2023 | +125.6% | $180.7M |
| Xoma Royalty CorporationCUSIP 98419J206 | June 30, 2020 | +115.1% | $322.7M |
| AVTXAvalo Therapeutics Inc | September 30, 2024 | +94.5% | $38.4M |
| TYRATyra Biosciences Inc | September 30, 2021 | +81.6% | $47.1M |
Sold off last quarter
- CMPXCompass Therapeutics Inc was $41.1M
- SEPNSepterna Inc was $32.5M
- Immunic IncCUSIP 4525EP101 was $8.5M
- Engene Holdings IncCUSIP 29286M113 was $2.5M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +26.2% | +14.8% |
| March 31, 2026 | +5.2% | −4.6% |
| December 31, 2025 | +46.8% | +2.4% |
| June 30, 2025 | +18.0% | +10.5% |
| March 31, 2025 | −19.6% | −4.6% |
| December 31, 2024 | −8.8% | +2.1% |
| September 30, 2024 | +8.9% | +5.4% |
| June 30, 2024 | −6.9% | +4.0% |
| March 31, 2024 | +4.5% | +10.0% |
| December 31, 2023 | +11.9% | +11.2% |
| September 30, 2023 | −3.4% | −3.6% |
| June 30, 2023 | +34.3% | +8.3% |
| March 31, 2023 | +3.1% | +7.0% |
| December 31, 2022 | +1.6% | +7.1% |
| September 30, 2022 | +10.1% | −5.3% |
| June 30, 2022 | −20.9% | −16.5% |
| March 31, 2022 | −19.2% | −4.9% |
| December 31, 2021 | −7.5% | +10.7% |
| September 30, 2021 | −6.6% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Bvf Inc/il Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1056807&type=13F-HR&dateb=&owner=include&count=40CIK 1056807
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1056807/000092189526002163/Filed August 14, 2026 · accession 0000921895-26-002163